发明名称 Anti-IL-23 heterodimer specific antibodies
摘要 The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.
申请公布号 US9127057(B2) 申请公布日期 2015.09.08
申请号 US201113810474 申请日期 2011.07.20
申请人 Teva Pharmaceuticals Ausralia Pty Ltd 发明人 Clarke Adam William;Doyle Anthony G.;Pollard Matthew;Tran Stephen
分类号 A61K39/395;C07K16/24;A61K39/00 主分类号 A61K39/395
代理机构 Stradley Ronon Stevens & Young, LLP 代理人 Stradley Ronon Stevens & Young, LLP
主权项 1. An isolated or recombinant antibody or antigen-binding fragment thereof that specifically binds to IL-23, comprising a heavy chain CDR1comprising the amino acid sequence of SEQ ID NO: 8, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 9 or 22, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 10, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, a light chain CDR2comprising the amino acid sequence of SEQ ID NO: 14, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 15.
地址 Macquarie Park, NSW AU